Last update Nov. 15, 2022

Becaplermin

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

It is a recombinant human platelet-derived growth factor which is indicated for treatment of diabetic foot. It is applied topically.

At the date of the last update, we found no published data on its excretion in breast milk.

Systemic absorption through skin lesion is not significant (Aizpurua 2004, Balfour 1999). Its high molecular weight and minimal systemic absorption makes it unlikely that it will pass into milk in significant amounts.

Due to its protein nature it would be digested and inactivated in the gastrointestinal tract. This low oral bioavailability minimizes the passage into plasma of the infant from ingested breast milk.

It is advisable to wash hands thoroughly and avoid applying it on the breast.

 

Alternatives

We do not have alternatives for Becaplermin since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Becaplermin is also known as


Becaplermin in other languages or writings:

Tradenames

Main tradenames from several countries containing Becaplermin in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. Dermat: ≈0 %
Molecular weight 12.294 daltons

References

  1. Aizpurua I. et al. Becaplermina. Informe de evaluación. 2004 Full text (link to original source) Full text (in our servers)
  2. Balfour JA, Noble S. Becaplermin. BioDrugs. 1999 May;11(5):359-64. Abstract

Total visits

3,091

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM